公开(公告)号：US20150196487A1

公开(公告)日：2015-07-16

申请号：US14632863

申请日：2015-02-26

Applicant: MERIAL LIMITED

Inventor： Noel Joseph Francois Detraz ,  Guillaume Rigaut

IPC: A61K9/107 ,  A61K9/00 ,  A61K47/06 ,  A61K39/39 ,  A61K39/135 ,  A61K45/06 ,  A61K39/12 ,  C12N7/00 ,  A61K47/26

CPC classification number: A61K39/00 ,  A61K9/0019 ,  A61K9/107 ,  A61K39/0241 ,  A61K39/12 ,  A61K39/125 ,  A61K39/135 ,  A61K39/39 ,  A61K45/06 ,  A61K47/06 ,  A61K47/26 ,  A61K2039/52 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/55577 ,  C12N7/00 ,  C12N2750/00022 ,  C12N2750/00034 ,  C12N2750/10034 ,  C12N2770/32022 ,  C12N2770/32134

Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.

Abstract translation: 本发明提供一种新型的水包油（O / W）乳液，其在细菌或病毒悬浮液，特别是浓缩和非纯化（粗提取物）或最低限纯化的存在下具有增加的稳定性。 本发明的乳液可用作递送包含至少一种免疫原的药物组合物，特别是选自灭活病原体，减毒病原体，亚单位，重组表达载体的免疫原的载体 ，以及质粒或其组合。

公开(公告)号：US20110045019A1

公开(公告)日：2011-02-24

申请号：US12861378

申请日：2010-08-23

Applicant: XIANG-JIN MENG ,  YAOWEI HUANG

Inventor： XIANG-JIN MENG ,  YAOWEI HUANG

IPC: A61K39/12 ,  C12N15/33 ,  C12N15/70 ,  C12N1/21 ,  C12N7/00 ,  C12Q1/70 ,  G01N33/53

CPC classification number: G01N33/56983 ,  A61K39/12 ,  A61K2039/552 ,  C07K14/005 ,  C07K16/081 ,  C12N7/00 ,  C12N2750/00021 ,  C12N2750/00022 ,  C12N2750/00034 ,  C12N2750/14034 ,  C12Q1/701 ,  G01N2333/01 ,  G01N2333/085 ,  G01N2469/20

Abstract: The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine Torque teno virus (PTTV) genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA. The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same. The present invention further provides live, attenuated, vector-expressed and purified recombinant capsid subunit or killed viral vaccines for protection against PTTV infection. The present invention additionally provides subunit vaccines comprising PTTV specific gene products, especially ORF1 capsid gene product for protection against PTTV infection. Further, the present invention provides methods for diagnosing PTTV infection via polymerase chain reaction (PCR) using specific primer for PTTV1, PTTV2, and individual PTTV1 genotypes. Finally, the present invention provides methods for diagnosing PTTV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies.

Abstract translation: 本发明提供了含有编码猪扭转腱病毒（PTTV）基因型或亚型PTTV1a-VA，PTTV1b-VA，PTTV2b-VA和PTTV2c-VA的多核酸分子的四种纯化制剂。 本发明还提供含有感染性核酸基因组分子的感染性DNA克隆，生物功能质粒或病毒载体。 本发明进一步提供活的，减毒的载体表达和纯化的重组衣壳亚单位或灭活的病毒疫苗以防止PTTV感染。 本发明另外提供了包含PTTV特异性基因产物的亚单位疫苗，特别是用于保护免受PTTV感染的ORF1衣壳基因产物。 此外，本发明提供了使用PTTV1，PTTV2和个体PTTV1基因型的特异性引物通过聚合酶链反应（PCR）诊断PTTV感染的方法。 最后，本发明提供了通过免疫学方法诊断PTTV感染的方法，例如使用PTTV特异性抗原检测血清PTTV特异性抗体的酶联免疫吸附测定（ELISA）和蛋白质印迹。

公开(公告)号：US20240000914A1

公开(公告)日：2024-01-04

申请号：US18250621

申请日：2021-10-29

Applicant: FLAGSHIP PIONEERING INNOVATIONS V, INC.

Inventor： Simon DELAGRAVE ,  Fernando Martin DIAZ ,  Jared David PITTS ,  Kevin James LEBO ,  Joseph Louis TIMPONA ,  Nicole Marie BOISVERT

IPC: A61K39/12 ,  C12N7/00 ,  C12N15/86 ,  C12N1/04

CPC classification number: A61K39/12 ,  C12N7/00 ,  C12N15/86 ,  C12N1/04 ,  C12N2750/00021 ,  C12N2750/00023 ,  C12N2750/00034 ,  C12N2750/00043 ,  A61K2039/5256

Abstract: This invention relates generally to compositions for making C A Vectors and uses thereof.

公开(公告)号：US20140335110A1

公开(公告)日：2014-11-13

申请号：US14255931

申请日：2014-04-17

Applicant: Sergey B. ONIKIENKO ,  Alexander V. ZEMLYANOI ,  Boris A. MARGULIS ,  Irina V. GUZHOVA ,  Anna A. PIMENOVA

Inventor： Sergey B. ONIKIENKO ,  Alexander V. ZEMLYANOI ,  Boris A. MARGULIS ,  Irina V. GUZHOVA ,  Anna A. PIMENOVA

IPC: A61K39/29 ,  C12N7/00 ,  A61K39/145

CPC classification number: A61K39/29 ,  A61K39/095 ,  A61K39/12 ,  A61K39/145 ,  A61K39/292 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55516 ,  A61N5/0613 ,  A61N2005/0659 ,  A61N2005/0662 ,  A61N2005/067 ,  C12N7/00 ,  C12N2730/10134 ,  C12N2750/00034 ,  C12N2760/16034 ,  C12N2760/16134

Abstract: The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine.

Abstract translation: 与先前未暴露于非破坏性激光辐射的受试者的免疫应答相比，本发明涉及用于在先前暴露于非破坏性激光辐射的受试者中产生增强的免疫应答的疫苗。 本发明还涉及与不使用激光辐射的免疫应答相比，包含疫苗的组合物与非破坏性激光辐射组合使用以产生来自受试者的增强的免疫应答的用途。 激光曝光作为疫苗的佐剂，增加疫苗的功效和/或效力。

公开(公告)号：US20110129494A1

公开(公告)日：2011-06-02

申请号：US12878630

申请日：2010-09-09

Applicant: Noel Joseph Francois Detraz ,  Guillaume Rigaut

Inventor： Noel Joseph Francois Detraz ,  Guillaume Rigaut

IPC: A61K39/12 ,  A61K39/00 ,  A61K39/02 ,  A61K39/002 ,  A61P37/00

CPC classification number: A61K39/00 ,  A61K9/0019 ,  A61K9/107 ,  A61K39/0241 ,  A61K39/12 ,  A61K39/125 ,  A61K39/135 ,  A61K39/39 ,  A61K45/06 ,  A61K47/06 ,  A61K47/26 ,  A61K2039/52 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/55577 ,  C12N7/00 ,  C12N2750/00022 ,  C12N2750/00034 ,  C12N2750/10034 ,  C12N2770/32022 ,  C12N2770/32134

Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.

Abstract translation: 本发明提供一种新型的水包油（O / W）乳液，其在细菌或病毒悬浮液，特别是浓缩和非纯化（粗提取物）或最低限纯化的存在下具有增加的稳定性。 本发明的乳液可用作递送包含至少一种免疫原的药物组合物，特别是选自灭活病原体，减毒病原体，亚单位，重组表达载体的免疫原的载体 ，以及质粒或其组合。

公开(公告)号：US20110059116A1

公开(公告)日：2011-03-10

申请号：US12754081

申请日：2010-04-05

Applicant: Sergey B. ONIKIENKO ,  Alexander V. ZEMLYANOI ,  Boris A. MARGULIS ,  Irina V. GUZHOVA ,  Anna A. PIMENOVA

Inventor： Sergey B. ONIKIENKO ,  Alexander V. ZEMLYANOI ,  Boris A. MARGULIS ,  Irina V. GUZHOVA ,  Anna A. PIMENOVA

IPC: A61K39/00 ,  A61P31/00

CPC classification number: A61K39/29 ,  A61K39/095 ,  A61K39/12 ,  A61K39/145 ,  A61K39/292 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55516 ,  A61N5/0613 ,  A61N2005/0659 ,  A61N2005/0662 ,  A61N2005/067 ,  C12N7/00 ,  C12N2730/10134 ,  C12N2750/00034 ,  C12N2760/16034 ,  C12N2760/16134

Abstract: The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine.

Abstract translation: 与先前未暴露于非破坏性激光辐射的受试者的免疫应答相比，本发明涉及用于在先前暴露于非破坏性激光辐射的受试者中产生增强的免疫应答的疫苗。 本发明还涉及与不使用激光辐射的免疫应答相比，包含疫苗的组合物与非破坏性激光辐射组合使用以产生来自受试者的增强的免疫应答的用途。 激光曝光作为疫苗的佐剂，增加疫苗的功效和/或效力。

公开(公告)号：US20090269282A1

公开(公告)日：2009-10-29

申请号：US12311260

申请日：2007-09-25

Applicant: John A. Ellis

Inventor： John A. Ellis

IPC: A61K49/00 ,  A61M37/00 ,  A61K39/12 ,  G01N33/53 ,  G01N33/569 ,  C12Q1/70

CPC classification number: A61K39/12 ,  A61K39/00 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  C12N2750/00034 ,  C12N2750/10011

Abstract: Compositions and methods for treating, preventing and diagnosing Torque teno virus (TTV) infection in pigs are disclosed. Also described are methods of identifying compounds for the treatment and prevention of TTV infection, as well as TTV animal models and methods of producing the same.

Abstract translation: 公开了用于治疗，预防和诊断猪扭转腱病毒（TTV）感染的组合物和方法。 还描述了鉴定用于治疗和预防TTV感染的化合物的方法，以及TTV动物模型及其制备方法。

公开(公告)号：US09624511B2

公开(公告)日：2017-04-18

申请号：US14479803

申请日：2014-09-08

Applicant: Deutsches Krebsforschungszentrum

Inventor： Harald zur Hausen ,  Ethel-Michele de Villiers

IPC: C12N15/86 ,  C12N7/00 ,  C12Q1/70 ,  C07K14/005

CPC classification number: C12N15/86 ,  C07K14/005 ,  C12N7/00 ,  C12N2750/00021 ,  C12N2750/00022 ,  C12N2750/00034 ,  C12N2750/00043 ,  C12Q1/701

Abstract: Described are single-stranded new sequences of TT viruses, rearranged TTV sequences and hybrid molecules of a specific TT virus sequence and host cell DNA that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. In addition, it relates to the use of such molecules as gene vectors and artificial chromosomes.

公开(公告)号：US20160266116A1

公开(公告)日：2016-09-15

申请号：US14978413

申请日：2015-12-22

Applicant: Virginia Tech Intellectual Properties

Inventor： Xiang-Jin Meng ,  Yaowei Huang

IPC: G01N33/569 ,  C12N7/00 ,  A61K39/12

CPC classification number: G01N33/56983 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/552 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2750/00021 ,  C12N2750/00022 ,  C12N2750/00034 ,  C12N2750/00043 ,  C12Q1/701 ,  G01N2333/01 ,  G01N2469/20

Abstract: The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of Torque teno sus virus (TTsuV). The present invention also provides methods for diagnosing TTsuV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies which indicate infections TTsuV1, TTsuV2, and individual TTsuV1 genotypes.

公开(公告)号：US09249192B2

公开(公告)日：2016-02-02

申请号：US13840805

申请日：2013-03-15

Applicant: Virginia Tech Intellectual Properties, Inc.

Inventor： Xiang-Jin Meng ,  Yaowei Huang

IPC: C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  A61K39/12 ,  G01N33/569 ,  C12Q1/70 ,  A61K39/00

CPC classification number: G01N33/56983 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/552 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2750/00021 ,  C12N2750/00022 ,  C12N2750/00034 ,  C12N2750/00043 ,  C12Q1/701 ,  G01N2333/01 ,  G01N2469/20

Abstract: The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of Torque teno sus virus (TTsuV). The present invention also provides methods for diagnosing TTsuV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies which indicate infections TTsuV1, TTsuV2, and individual TTsuV1 genotypes.

Abstract translation: 本发明还提供感染性DNA克隆，含有Torque teno sus病毒（TTsuV）的感染性核酸基因组分子的生物功能质粒或病毒载体。 本发明还提供了通过免疫学方法例如酶联免疫吸附测定（ELISA）和使用PTTV特异性抗原检测表明感染TTsuV1，TTsuV2和个体TTsuV1基因型的血清PTTV特异性抗体的蛋白质印迹来诊断TTsuV感染的方法。